1. Home
  2. IMAX vs STOK Comparison

IMAX vs STOK Comparison

Compare IMAX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imax Corporation

IMAX

Imax Corporation

HOLD

Current Price

$37.05

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$30.65

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMAX
STOK
Founded
1967
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
IMAX
STOK
Price
$37.05
$30.65
Analyst Decision
Buy
Strong Buy
Analyst Count
9
9
Target Price
$36.44
$31.00
AVG Volume (30 Days)
1.3M
1.2M
Earning Date
10-23-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
62.41
N/A
EPS
0.71
0.68
Revenue
$377,677,000.00
$205,632,000.00
Revenue This Year
$17.45
$416.54
Revenue Next Year
$6.19
N/A
P/E Ratio
$52.14
$45.14
Revenue Growth
9.30
1128.17
52 Week Low
$20.48
$5.35
52 Week High
$37.57
$38.69

Technical Indicators

Market Signals
Indicator
IMAX
STOK
Relative Strength Index (RSI) 69.08 60.05
Support Level $35.10 $28.51
Resistance Level $37.21 $29.38
Average True Range (ATR) 1.16 1.99
MACD 0.09 0.55
Stochastic Oscillator 84.20 93.67

Price Performance

Historical Comparison
IMAX
STOK

About IMAX Imax Corporation

Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: